QR код

Subclonal response heterogeneity to define cancer organoid therapeutic sensitivity

Abstract Tumor heterogeneity is predicted to confer inferior clinical outcomes with precision-based strategies, however, modeling heterogeneity in a manner that still represents the tumor of origin remains a formidable challenge. Sequencing technologies are limited in their ability to identify rare...

Повний опис

Збережено в:
Автори: Jeremy D. Kratz, Shujah Rehman, Katherine A. Johnson, Amani A. Gillette, Aishwarya Sunil, Peter F. Favreau, Cheri A. Pasch, Devon Miller, Lucas C. Zarling, Austin H. Yeung, Linda Clipson, Samantha J. Anderson, Alyssa K. Steimle, Carley M. Sprackling, Kayla K. Lemmon, Daniel E. Abbott, Mark E. Burkard, Michael F. Bassetti, Jens C. Eickhoff, Eugene F. Foley, Charles P. Heise, Randall J. Kimple, Elise H. Lawson, Noelle K. LoConte, Sam J. Lubner, Daniel L. Mulkerin, Kristina A. Matkowskyj, Cristina B. Sanger, Nataliya V. Uboha, Sean J. Mcilwain, Irene M. Ong, Evie H. Carchman, Melissa C. Skala, Dustin A. Deming
Формат: Artigo
Мова:Inglês
Опубліковано: Nature Portfolio 2025-04-01
Серія:Scientific Reports
Предмети:
Organoids
Clonal heterogeneity
Colorectal cancer
Targeted therapy
EGFR
Онлайн доступ:https://doi.org/10.1038/s41598-025-96204-2
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси